SCHEMBL6416039

SCHEMBL6416039

CC(C)(C)OC(=O)NNc1nc2nonc2nc1Nc1ccccc1NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 3/20 0.40
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
CDKN1A P38936 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
BRD4 O60885 2/20 0.36
METAP1 P53582 1/20 0.35
P2RX7 Q99572 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419677 0.85 GAA (0.49) MEN1KMT2ANPC1GAARAB9A
SCHEMBL6432336 0.80 SMN1; SMN2 (0.37) MEN1KMT2AGAALMNAPOLB
SCHEMBL6419799 0.79 SMN1; SMN2 (0.48) MEN1KMT2ANPC1GAARAB9A
SCHEMBL6414619 0.78 MEN1 (0.46) MEN1KMT2ANPC1GAARAB9A
SCHEMBL6416313 0.78 MAPT (0.47) MEN1KMT2ANPC1GAARAB9A
SCHEMBL6416982 0.76 MAPT (0.45) MEN1KMT2ANPC1GAARAB9A
SCHEMBL6414172 0.74 GAA (0.40) MEN1KMT2ANPC1GAARAB9A
SCHEMBL6414113 0.74 EGFR (0.49) MEN1KMT2APOLBSMN1; SMN2TP53
SCHEMBL6414257 0.73 GAA (0.39) MEN1KMT2ANPC1GAARAB9A
SCHEMBL2880191 0.73 LMNA (0.54) MEN1KMT2ANPC1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885NPC1 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.